PMV Pharmaceuticals, Inc.

NasdaqGS:PMVP Voorraadrapport

Marktkapitalisatie: US$84.5m

PMV Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

De CEO PMV Pharmaceuticals is David Mack, benoemd in Jul2013, heeft een ambtstermijn van 11.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.21M, bestaande uit 26.5% salaris en 73.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.26% van de aandelen van het bedrijf, ter waarde $ 1.06M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.7 jaar en 3.8 jaar.

Belangrijke informatie

David Mack

Algemeen directeur

US$2.2m

Totale compensatie

Percentage CEO-salaris26.5%
Dienstverband CEO11.3yrs
Eigendom CEO1.3%
Management gemiddelde ambtstermijn3.7yrs
Gemiddelde ambtstermijn bestuur3.8yrs

Recente managementupdates

Recent updates

Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Deliver On Growth Plans?

Aug 04
Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Deliver On Growth Plans?

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Apr 20
Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Dec 22
Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

We Think PMV Pharmaceuticals (NASDAQ:PMVP) Can Afford To Drive Business Growth

Sep 08
We Think PMV Pharmaceuticals (NASDAQ:PMVP) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

May 10
Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans

Jan 11
PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Sep 22
Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

PMV Pharmaceuticals GAAP EPS of -$0.38 beats by $0.04

Aug 09

PMV Pharma joins Merck to study lead candidate with Keytruda

Jul 18

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Jun 09
Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

Feb 23
Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Nov 05
Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

Jul 23
Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Strong Position To Grow Its Business

Apr 09
PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Strong Position To Grow Its Business

Do Institutions Own PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares?

Dec 25
Do Institutions Own PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares?

PMV Pharmaceuticals reports Q3 results

Nov 13

Analyse CEO-vergoeding

Hoe is David Mack's beloning veranderd ten opzichte van PMV Pharmaceuticals's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$49m

Mar 31 2024n/an/a

-US$65m

Dec 31 2023US$2mUS$586k

-US$69m

Sep 30 2023n/an/a

-US$73m

Jun 30 2023n/an/a

-US$74m

Mar 31 2023n/an/a

-US$74m

Dec 31 2022US$4mUS$564k

-US$73m

Sep 30 2022n/an/a

-US$72m

Jun 30 2022n/an/a

-US$69m

Mar 31 2022n/an/a

-US$65m

Dec 31 2021US$4mUS$545k

-US$58m

Sep 30 2021n/an/a

-US$50m

Jun 30 2021n/an/a

-US$44m

Mar 31 2021n/an/a

-US$39m

Dec 31 2020US$1mUS$495k

-US$34m

Sep 30 2020n/an/a

-US$31m

Jun 30 2020n/an/a

-US$28m

Mar 31 2020n/an/a

-US$27m

Dec 31 2019US$628kUS$461k

-US$25m

Compensatie versus markt: De totale vergoeding ($USD 2.21M ) David } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 653.78K ).

Compensatie versus inkomsten: De vergoeding van David is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.


CEO

David Mack (62 yo)

11.3yrs

Tenure

US$2,209,795

Compensatie

Dr. David H. Mack, Ph D., Co-founded PMV Pharmaceuticals, Inc. in 2013 and also serves as its President and Chief Executive Officer since July 2013. Dr. Mack joined the PMV Pharmaceuticals, Inc. in 2013.D...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
David Mack
Co-Founder11.3yrsUS$2.21m1.26%
$ 1.1m
Arnold Levine
Co-Founder11.8yrsUS$220.27k0.80%
$ 672.1k
Deepika Jalota
Chief Development Officer5.4yrsUS$1.10m0.044%
$ 37.3k
Michael Carulli
Chief Financial Officerless than a yeargeen gegevens0.012%
$ 10.1k
Robert Ticktin
General Counsel4.3yrsgeen gegevensgeen gegevens
Tim Smith
Senior VP and Head of Corporate Development & Investor Relations3.2yrsgeen gegevensgeen gegevens
Crystal Zuckerman
Vice President of Human Resources1.8yrsgeen gegevensgeen gegevens
Binh Vu
Senior Vice President of Drug Discovery & CMCno datageen gegevensgeen gegevens
Marc Fellous
Senior VP and Head of Clinical Development & Medical Affairs1.5yrsgeen gegevensgeen gegevens
Laura De Leon
VP & Head of Clinical Operationsno datageen gegevensgeen gegevens

3.7yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van PMVP wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.7 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
David Mack
Co-Founder11.4yrsUS$2.21m1.26%
$ 1.1m
Arnold Levine
Co-Founder11.4yrsUS$220.27k0.80%
$ 672.1k
Charles Sawyers
Member of Clinical Advisory Boardno datageen gegevensgeen gegevens
Carol Gallagher
Independent Director2yrsUS$124.27kgeen gegevens
Richard Heyman
Independent Chairman of the Board of Directors & Member of Scientific Advisory Board4.4yrsUS$176.77k0%
$ 0
Scott Lowe
Chairman of Scientific Advisory Boardless than a yeargeen gegevensgeen gegevens
Charles Baum
Independent Director & Chair of Clinical Advisory Board3.6yrsUS$133.27k0%
$ 0
Laurie Stelzer
Independent Director4.3yrsUS$140.27k0%
$ 0
Kirsten Flowers
Independent Director2.8yrsUS$127.77k0%
$ 0
Guillermina Lozano
Member of Scientific Advisory Board3.8yrsgeen gegevensgeen gegevens

3.8yrs

Gemiddelde duur

63.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van PMVP wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).